Statement from PointsBet Canada on the official launch of Ontario’s sports wagering market

TORONTO, April 4, 2022 /PRNewswire/ — The following is a statement from Scott Vanderwel, CEO of PointsBet Canada, on the official launch of Ontario’s sports wagering market. “Today is a great day for Ontario sports fans! On behalf of the entire PointsBet Canada team, I’d like to share…

Blood Viscometer Market to grow at a CAGR of 6.75% by 2026| Increasing Vascular Diseases to Boost Growth |17000+ Technavio Reports

NEW YORK, April 4, 2022 /PRNewswire/ — The blood viscometer market is fragmented and the vendors are deploying growth strategies such as quality, price, service, brand image, distribution, and marketing to compete in the market. A and D Co Ltd., Analytical Technology and Control Ltd.,…

Nuclear Missiles and Bombs Market to Reach $126.34 Billion, Globally, by 2030 at 5.4% CAGR: Allied Market Research

Rise in geopolitical conflicts and surge in defense budget allocations drive the global nuclear missiles and bombs market. PORTLAND, Ore., April 4, 2022 /PRNewswire/ — Allied Market Research recently published a report, titled, “Nuclear Bombs and Missiles Market by Type (Aircraft…

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Meta Platforms, Inc. Investors of a Lead Plaintiff Deadline of May 9, 2022

NEW YORK, April 4, 2022 /PRNewswire/ — Attention Meta Platforms, Inc. (“Meta Platforms, Inc.”) (NASDAQ: FB) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between March 2, 2021 and February 2, 2022. If…

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Akebia Investors of a Lead Plaintiff Deadline of May 13, 2022

NEW YORK, April 4, 2022 /PRNewswire/ — Attention Akebia Therapeutics, Inc. (“Akebia”) (NASDAQ: AKBA) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between June 28, 2018 and September 2, 2020. If you…

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Celsius Investors of a Lead Plaintiff Deadline of May 16, 2022

NEW YORK, April 4, 2022 /PRNewswire/ — Attention Celsius Holdings, Inc. (“Celsius”) (NASDAQ: CELH) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between August 12, 2021 and March 1, 2022. If you…

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Grab Holdings Investors of a Lead Plaintiff Deadline of May 16, 2022

NEW YORK, April 4, 2022 /PRNewswire/ — Attention Grab Holdings Limited (“Grab Holdings”) (NASDAQ: GRAB) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between November 12, 2021 and March 2, 2022. If…

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Telefonaktiebolaget LM Ericsson Investors of a Lead Plaintiff Deadline of May 2, 2022

NEW YORK, April 4, 2022 /PRNewswire/ — Attention Telefonaktiebolaget LM Ericsson (“Telefonaktiebolaget LM Ericsson”) (NASDAQ: ERIC) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between April 27, 2017…

Pharming anuncia datos positivos del ensayo de fase II/III de leniolisib presentado en la Reunión Anual de la Sociedad de Inmunología Clínica 2022

LEIDEN, Países Bajos, 3 de abril de 2022 /PRNewswire/ — Pharming Group N.V. (“Pharming” o “la Compañía”) (EURONEXT Ámsterdam: PHARM/Nasdaq: PHAR) anuncia nuevos datos del ensayo pivotal de fase II/III de leniolisib para el tratamiento del síndrome de fosfoinositido 3-quinasa delta…

Pharming anuncia dados positivos do estudo clínico de Leniolisibe de fase II/III apresentados na Reunião Anual da Sociedade de Imunologia Clínica de 2022

LEIDA, Países Baixos, 3 de abril de 2022 /PRNewswire/ — Pharming Group N.V. (“Pharming” ou “a Empresa”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) anuncia novos dados do estudo clínico pivotal do Leniolisibe de fase II/III para o tratamento de síndrome de fosfoinositídeo 3-quinase delta…

« Previous Page — Next Page »